| Total | Germany | France | UK | Spain | Poland |
BASE: total respondents | 1513 | 301 | 304 | 300 | 308 | 300 |
Application time (Frequency/Percentage) | ||||||
Morning | 504 33.3% | 109 36.2% | 142 46.7% | 82 27.3% | 53 17.2% | 118 39.3% |
Afternoon | 328 21.7% | 56 18.6% | 78 25.7% | 56 18.7% | 45 14.6% | 93 31.0% |
Evening | 1,347 89.0% | 272 90.4% | 265 87.2% | 279 93.0% | 284 92.2% | 247 82.3% |
Method of administration (Frequency/Percentage) | ||||||
Topical/External | 1055 69.7% | 197 65.4% | 167 54.9% | 181 60.3% | 218 70.8% | 292 97.3% |
Inhalation | 131 8.7% | 25 8.3% | 45 14.8% | 35 11.7% | 26 8.4% | 0 0.0% |
Both topical and inhalation | 319 21.1% | 79 26.2% | 92 30.3% | 84 28.0% | 64 20.8% | 0 0.0% |
Other | 8 0.5% | 0 0.0% | 0 0.0% | 0 0.0% | 0 0.0% | 8 2.7% |
Day of disease when VVR was used (Frequency/Percentage) | ||||||
Day 1 - 2 | 706 46.7% | 167 55.5% | 48 15.8% | 150 50.0% | 146 47.4% | 195 65.0% |
Day 3 - 4 | 1,136 75.1% | 237 78.7% | 212 69.7% | 239 79.7% | 222 72.1% | 226 75.3% |
Day 5 - 6 | 394 26.0% | 97 32.2% | 55 18.1% | 102 34.0% | 54 17.5% | 86 28.7% |